GM
VRTX icon

GeoWealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

GeoWealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$669K Buy
1,345
+138
+11% +$61.2K 0.02% 425
2026
Q1 		$539K Buy
1,207
+197
+20% +$91.9K 0.02% 459
2025
Q4 		$458K Sell
1,010
-8
-0.8% -$3.45K 0.02% 465
2025
Q3 		$399K Buy
1,018
+64
+7% +$26.7K 0.01% 497
2025
Q2 		$425K Sell
954
-89
-9% -$41K 0.02% 441
2025
Q1 		$506K Sell
1,043
-270
-21% -$126K 0.02% 418
2024
Q4 		$529K Sell
1,313
-1,292
-50% -$599K 0.02% 455
2024
Q3 		$1.21M Buy
2,605
+1,346
+107% +$647K 0.04% 266
2024
Q2 		$590K Buy
1,259
+212
+20% +$92K 0.03% 389
2024
Q1 		$438K Buy
+1,047
New +$443K 0.02% 477

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

GeoWealth Management's VRTX Position: Q2 2026 in Review

GeoWealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 11% in Q2 2026, buying an estimated $61.2K and bringing the position to 1,345 shares worth $669K. The position accounts for 0.02% of the portfolio, ranked #425.

GeoWealth Management first reported a position in VRTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.21M in Q3 2024. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • GeoWealth Management held 1,345 shares of Vertex Pharmaceuticals worth $669K as of Q2 2026.
  • GeoWealth Management bought 138 Vertex Pharmaceuticals shares in Q2 2026, an estimated $61.2K.
  • Vertex Pharmaceuticals made up 0.02% of GeoWealth Management's portfolio in Q2 2026, its #425 holding.
  • GeoWealth Management first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • GeoWealth Management's Vertex Pharmaceuticals position peaked at $1.21M in Q3 2024.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on GeoWealth Management's 13F filing for Q2 2026, filed 30 Jul 2026.